Padda Provides Update on the Race to the Frontline With Immunotherapy in Lung Cancer – Targeted Oncology
Targeted Oncology |
Padda Provides Update on the Race to the Frontline With Immunotherapy in Lung Cancer
Targeted Oncology Currently, pembrolizumab (Keytruda) is the only immunotherapy agent approved in the frontline setting for patients with non–small cell lung cancer (NSCLC); however, many other immunotherapy agents and combination regimens are in development that are … |
